Atria Wealth Solutions Inc. raised its position in ARK Genomic Revolution ETF (BATS:ARKG – Free Report) by 121.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 19,792 shares of the company’s stock after acquiring an additional 10,841 shares during the period. Atria Wealth Solutions Inc.’s holdings in ARK Genomic Revolution ETF were worth $466,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. JPMorgan Chase & Co. increased its holdings in shares of ARK Genomic Revolution ETF by 31.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,955,279 shares of the company’s stock valued at $75,655,000 after purchasing an additional 698,701 shares in the last quarter. Barclays PLC boosted its stake in shares of ARK Genomic Revolution ETF by 252.7% during the 3rd quarter. Barclays PLC now owns 285,108 shares of the company’s stock worth $7,299,000 after acquiring an additional 204,283 shares in the last quarter. PFM Health Sciences LP acquired a new stake in shares of ARK Genomic Revolution ETF in the 3rd quarter worth approximately $2,226,000. Quadrature Capital Ltd purchased a new position in ARK Genomic Revolution ETF in the 3rd quarter valued at approximately $1,970,000. Finally, Elmwood Wealth Management Inc. raised its holdings in ARK Genomic Revolution ETF by 7.7% during the fourth quarter. Elmwood Wealth Management Inc. now owns 62,191 shares of the company’s stock worth $1,464,000 after purchasing an additional 4,425 shares during the last quarter.
ARK Genomic Revolution ETF Trading Up 4.0 %
ARK Genomic Revolution ETF stock opened at $24.54 on Friday. The firm has a fifty day moving average price of $25.93 and a two-hundred day moving average price of $25.40.
ARK Genomic Revolution ETF Profile
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Featured Articles
- Five stocks we like better than ARK Genomic Revolution ETF
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- How to Read Stock Charts for Beginners
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- What Are Some of the Best Large-Cap Stocks to Buy?
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Want to see what other hedge funds are holding ARKG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARK Genomic Revolution ETF (BATS:ARKG – Free Report).
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
